Table 6 Responses of the panelists before and after brainstorming for the questions for which there was change in consensus
Questions | Before brainstorming | After brainstorming | p-value* | ||
|---|---|---|---|---|---|
Disagreement n (%) | Agreement n (%) | Disagreement n (%) | Agreement n (%) | ||
Q05. Gene panel testing should be recommended for all cases. | 8 (29.6) | 19 (70.4) | 10 (37.0) | 17 (63.0) | 0.56 |
Q09. Following BCS and when the SLN is positive at upfront surgery, in addition to systemic treatment, radiotherapy should be recommended as local treatment. | 5 (18.5)a | 22 (81.5) | 11 (40.7) | 16 (59.3) | 0.02 |
Q22. In T2N0 patients submitted to simple mastectomy (removal of the NAC), radiotherapy of the thoracic wall should be recommended as routine. | 18 (66.7) | 9 (33.3) | 21 (77.8) | 6 (22.2) | 0.36 |
Q33. Following neoadjuvant treatment, staging exams should be requested again only in the case of partial response or progression. | 9 (33.3) | 18 (66.7) | 8 (29.6) | 19 (70.4) | 0.95 |
Q35. In patients with no BRCA germline mutation, platinum agents should be recommended in neoadjuvant treatment. | 11 (40.7) | 16 (59.3) | 7 (25.9) | 20 (74.1) | 0.24 |
Q36. In patients with the BRCA germline mutation, the use of platinum agents in neoadjuvant treatment should be recommended. | 11 (40.7) | 16 (59.3) | 5 (18.5) | 22 (81.5) | 0.07 |
Q37. In patients who will be submitted to neoadjuvant treatment, the addition of immunotherapy should be recommended as routine. | 13 (48.1) | 14 (51.9) | 5 (18.5) | 22 (81.5) | 0.02 |
Q38. In patients who will be submitted to neoadjuvant treatment, PD-L1 status should be taken into consideration when recommending immunotherapy. | 14 (51.9) | 13 (48.1) | 22 (81.5) | 5 (18.5) | 0.02 |
Q40. In patients who will be submitted to neoadjuvant treatment with immunotherapy, dose-dense anthracycline-based chemotherapy should be used. | 7 (25.9) | 20 (74.1) | 15 (55.6) | 12 (44.4) | 0.03 |
Q41. In patients with no BRCA germline mutation submitted to neoadjuvant treatment with immunotherapy and who achieve pCR, immunotherapy should be continued during adjuvant therapy. | 11 (40.7) | 16 (59.3) | 3 (11.1) | 24 (88.9) | 0.01 |
Q44. In patients with the BRCA germline mutation submitted to neoadjuvant therapy with immunotherapy and who achieve pCR, the use of adjuvant immunotherapy associated with olaparib should be suggested. | 18 (66.7) | 9 (33.3) | 8 (29.6) | 19 (70.4) | 0.77 |